1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Helix BioMedix, Inc.

Helix BioMedix, Inc.

HXBM
Helix BioMedix, Inc.US flagOther OTC
1.79
USD
- -
- -
402,227.00Market Cap
Helix BioMedix, Inc.
HXBM
(Other OTC)

Recent

price

1.79

P/E

ratio

- -

div

yld

- -

ROIC.AI

1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
TTM
FRC
- -
- -
- -
4.08
2.36
2.11
1.82
0.95
5.54
6.58
4.58
9.42
11.41
12.47
Revenue per Share
-82.1
-114.46
-123.57
-184.32
-85.37
-70.19
-55.06
-51.41
-40.98
-52.81
-44.15
-85.29
-15.02
-15.59
Basic EPS, GAAP
-61.32
-52.65
-105.53
-99.3
-63.83
-56.89
-48.7
-42.37
-38.66
-37.09
-36.42
-31
-13.87
-10.92
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
170.09
-336.52
-449.12
-624.49
-371.48
-384.09
-340.78
-323.76
-328.69
-374.92
-419.07
-481.38
-277.62
-289.91
Book Value per Share
174.65
0.43
-78.13
72.92
63.3
48.58
50.6
30.71
14.78
-24.19
-63.75
51.55
14.42
6.36
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
1
2
2
Sales/Revenue/Turnover
-62,171,400
-185,326,100
-188,612,200
-3,522.02
-3,630.77
-3,350.21
-3,065.57
-5,500.08
-758.41
-629.65
-822.43
-347.1
-127.12
-117.3
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-2
-2
-3
-3
-3
-3
-4
-3
-5
-4
-8
-2
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-64,928,600
-185,282,300
-207,880,700
-4,517.01
-3,612.17
-3,319.71
-3,023.06
-5,396.57
-740.18
-802.22
-964.82
-905.36
-131.58
-125.06
Profit Margin (%)
1
- -
-2
1
2
2
3
2
1
1
1
4
2
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
6
- -
- -
- -
LT Debt
1
1
-1
2
3
3
4
3
2
-2
-5
5
3
1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'12
Jun'12
Sep'12
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
12
20
11

Working Capital

FRC

•

in mil. unless spec.
Mar'12
Jun'12
Sep'12
Total Current Assets
2
2
1
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
1
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-56.49%
-56.75%
-47.99%
Free Cash Flow
3.63%
-5.85%
-17.97%
Net Income, GAAP
11.4%
8.26%
-67.73%
Sales/Revenue/Turnover
700,069.8%
156.91%
122.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
- -
- -
- -
- -
1
2011
- -
1
- -
- -
2
2012
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
-10.84
-11.02
-13.09
- -
-85.29
2011
-4.28
-3.77
-3.65
- -
-15.02
2012
-3.51
-4.03
-4.74
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -
Similar Companies
Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
Comera Life Sciences Holdings, Inc. (CMRAW)
Global Blood Therapeutics, Inc. (GBT)
Regenerative Medical Technology Group Inc. (RMTG)
Oncodesign S.A. (ALONC.PA)
Epizyme, Inc. (EPZM)
Business
Helix BioMedix, Inc. operates as a biopharmaceutical company centered on peptide discovery and development within the United States, primarily focusing on dermatology and skin health. The company is actively developing HB4208, a polypeptide DNA Damage Response enzyme, as a potential topical treatment for Xeroderma Pigmentosum (XP), an ultra-rare genetic skin condition, currently in preclinical stages. Beyond its pharmaceutical pipeline, Helix BioMedix leverages an extensive library of proprietary bioactive peptides for licensing, offering advanced ingredients for various cosmetic and personal care formulations. These peptides address needs in areas ranging from anti-aging to acne management, utilizing the body's innate immunity. Founded in 1988, the company maintains its headquarters in Bothell, Washington.